Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Your DevOps maturity journey – part 3

In order to be truly effective, DevOps relies on Continuous Delivery (CD), which, in turn, requires Continuous Integration (CI). The release of incremental software changes needs not only automated release mechanisms, but also testing, code quality, security and privacy controls, and validation steps. For organizations in a highly regulated environment such as healthcare, however, validation…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

In order to be truly effective, DevOps relies on Continuous Delivery (CD), which, in turn, requires Continuous Integration (CI). The release of incremental software changes needs not only automated release mechanisms, but also testing, code quality, security and privacy controls, and validation steps. For organizations in a highly regulated environment such as healthcare, however, validation must be taken a step further through the process of Continuous Validation (CV). This blog is more about true DevOps and where the rubber hits the road.

GalaxE can help you benchmark your current DevOps maturity and has provided a roadmap to reach your full potential. The first four tiers are:

Tier 0: Traditional Waterfall

Tier 1: Iterative Waterfall

Tier 2: Early Reviews, and 

Tier 3: Agile Team

Let’s take a look at the final four tiers:

Tier 4: Transition to Agile – As an organization transitions toward agile artifacts and practices, the day-to-day duties of personnel will change. Team members will incorporate more QA measures to test the performance of their software as it is being developed, such as a focus on “Defined as Ready” (DoR) and “Defined as Done” (DoD).

Tier 5: Agile Practices – The team completes the transition of any legacy artifacts and processes until they are all agile. The development team collaborates closely with business stakeholders to deliver frequent, usable versions of the product. Teams then use the knowledge they acquire to fix mistakes they’ve found and to build on the previous version.

Tier 6: CI/CV/CD (Continuous Integration/Continuous Validation/Continuous Development) – This is a proactive, test-driven approach that uses automation in build, test, and release mechanisms to ensure continuity and accuracy. Process tools such as test-driven development (TDD) and software mapping are used to create a series of specific test cases. Each step is integrated into the software, validated, and then used to develop the next iteration.

Tier 7: DevOps – DevOps emphasizes automation and monitoring during all steps of software development, from integration through validation and deployment. Through this approach, DevOps aims to create shorter development cycles, increase deployment frequency, and deliver more dependable releases to meet business objectives. This process allows for more frequent releases in order to “fail faster,” resulting in more dependable software.

What’s different about the GalaxE approach is the capabilities of our enablement tools GxMaps™, GxDash™, and GxQuality™, which are a natural progression from QA automation. Once integrated, these tools enhance redundancy, diversity, reliability, and fault tolerance at the highest of levels. Integrating these solutions into your business is essential for efficient adaptation to shifting markets, regulation, and customer demands. Without them, businesses risk being outpaced by the competition.

Learn more about GxMaps™ application dependency mapping software and how it can help you achieve DevOps environments at https://galaxe.com/gx-maps/.

Read more at galaxe.com

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

NextGen Invent’s Deepak Mittal argues for scoped healthcare AI pilots with early governance

NextGen Invent’s Deepak Mittal argues that healthcare AI pilots can begin with a reliable data subset and early governance. His performance figures are vendor claims, not independently verified results.

  • 01Deepak Mittal advocates starting with a defined problem and suitable data rather than waiting for perfect organization-wide data.
  • 02Some performance figures cited in the interview (for example, preparation time and model counts) are company-reported and not independently verified in this article.
  • 03NIST’s voluntary AI Risk Management Framework provides an independent structure for governance and risk evaluation.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512